Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma

Osteosarcoma Clinical Trial

Official title:

Observational - Gene Discovery in Osteosarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01807143
• Other study ID #: AOST10B1
• Secondary ID: NCI-2013-00124
• Status: Completed
• Phase: N/A
• First received: March 6, 2013
• Last updated: March 4, 2016
• Start date: January 2010

Study information

• Verified date: March 2016
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This clinical trial studies genetic biomarkers in tissue samples from patients with osteosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Description:

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective:

Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Samples from the COG Sampling Method: Non-Probability Sample

PRIMARY OBJECTIVES:

I. To use PET sequencing to analyze DNA from ten human primary osteosarcoma samples, along with matched normal tissue where available.

OUTLINE:

Tissue samples are analyzed for translocations and deletions and analyzed using polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Samples from the COG tissue repository

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Osteosarcoma

Intervention

Other:
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	Children's Oncology Group	Monrovia	California

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mapping and filtering of paired tags	Mapping of paired tags to reference genomes to identify aberrant pairs, caused by translocations, insertions, deletions and inversions.	Up to 2 years	No